Clinical-stage Phase 2 biotech developing first-in-class precision therapies for rare and inflammatory diseases via the GRID AI platform.
GEn1E Lifesciences is a clinical-stage Phase 2 company that advanced from early discovery to Phase 2 in 2.5 years using seed capital. It develops selective p38α:MK2 dual signal modulators with a differentiated mechanism of action that avoids non-specific immunosuppression. The lead asset GEn-1124 is in Phase 2 for ARDS. The proprietary GRID AI platform connects genes, pathways, proteins, diseases, and compounds via machine learning to accelerate drug discovery, yielding 21+ first-in-class compounds. GEn1E Lifesciences is a product of GEn1E Lifesciences.